Four new anti-cancer drugs leads identified

Four new anti-cancer drugs leads identified

3:48 AM, 2nd December 2011
Four new anti-cancer drugs leads identified
Jason Smith, M.Phil, biomolecular sciences from Macquarie University

SYDNEY, AUSTRALIA: Four new anti-cancer drug leads have been identified in a research paper published online in Bioorganic and Medicinal Chemistry.

Lead author Jason Smith undertook a comprehensive study that combined existing knowledge of an enzyme with a specifically tailored computational chemistry approach to identify novel inhibitors. The enzyme (indoleamine 2, 3-dioxygenase) has generated excitement among researchers over the last decade due to its increasingly recognised role as a drug target, particularly in cancer. Jason Smith is doing his doing M.Phil, biomolecular sciences from Macquarie University.

"Over the past ten years, scientists have learnt that compounds inhibiting this enzyme allow the immune system to attack cancer cells. They have found that if you use these inhibitors alone, they slow tumour growth. Even more exciting is that in combination with chemotherapy, these inhibitors have the potential to destroy a tumour entirely," explained Smith.

After conducting virtual screening of a database of almost 60,000 compounds, Smith found 18 compounds that could hold potential as inhibitors of this enzyme. He then tested them in the lab and found four compounds with particularly exciting prospects.

Smith sees much strength in the approach taken. "Computational chemistry means we don't have to spend years testing thousands of compounds in the lab. We can analyse all the potential compounds and narrow them down in a matter of 6 month's preparation and virtual screening, instead of years. In fact, after all the preparation and groundwork, the screening itself takes around 100 hours."

This research was conducted as part of collaboration between the Department of Chemistry and Biomolecular Sciences at Macquarie University and the School of Medical Sciences/Pharmacology, University of New South Wales.

Although the leads are a way off from clinical trials, Smith and the team are excited about the future development of this research. Smith, a completing Master of Philosophy student, plans to continue study on these enzyme inhibitors as part of a Doctoral degree in 2012.


© Macquarie University News 



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Chevron Phillips Chemical Completes Acquisition of PAO Plant in Belgium

TEXAS, US: Chevron Phillips Chemical International NV, a wholly owned subsidiary of Chevron Phillips Chemical Company LLC (Chevron Phillips Chemical ...

Read more
Sasol to divest from its operations in Iran

JOHANNESBURG, SOUTH AFRICA: South African petrochemicals group Sasol said it had entered talks to potentially divest from its operations in Iran, a ...

Read more
International Year of Chemistry- closing ceremony

BRUSSELS, BELGIUM: More than 800 people from 70 countries descended on Brussels to attend the International Year of Chemistry 2011 (IYC) official cl ...

Read more
Nufarm buys American Seed Company

  VICTORIA, AUSTRALIA: Nufarm, the Australian agricultural chemicals supplier has expanded its involvement in seeds by buying an American sunf ...

Read more
BASF to build a new plant in Korea for production of polyethersulfone

Yeosu, Korea: BASF will build a new plant to produce Ultrason® polyethersulfone (PESU), one of BASF’s high-performance thermoplastics, at ...

Read more
Evonik to supply hydrogen peroxide to Canada based Chemical Industry

ESSEN, GERMANY:  Evonik Industries has closed the deal to take over the hydrogen peroxide business from Kemira Chemicals Canada Inc. effective ...

Read more uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X